Developer of Botox lotion files for $58M IPO

New York City's Anterios is developing ANT-1207, a lotion containing the active ingredient of Botox (marketed by recently acquired Allergan) that can be applied on the skin via a 10-minute massage. Anterios recently filed for a $58 million IPO with the Securities and Exchange Commission. The company say its candidate is being studied for all the indications of the conventional, injectable Botox like excessive sweating and facial wrinkles, as well as new ones like acne. It believes the new formulation can expand the market for the drug by avoiding the complications of injection like bleeding and pain. In addition, the company is developing a liquid formulation of injectable Botox to avoid the need for reconstitution following freeze drying. Newly listed Revance Therapeutics ($RVNC) is also developing a topical formulation of Botox. The company is up 30% since its February market debut. More

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…